Document is current
Any future updates will be listed below
-
Authors
Vencio, Sérgio https://orcid.org/0000-0001-9283-486X
Vianna, André Gustavo Daher
da Silva, Mariana Arruda Camara Ferreira
Precoma, Dalton Bertolim
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03786406 at ClinicalTrials.govnct03811288 at ClinicalTrials.govDocuments that mention this clinical trial
Contemporary (2019) prevalence of cardiovascular disease in adults with type 2 diabetes in Brazil: the cross-sectional CAPTURE study
https://doi.org/10.1186/s13098-021-00775-9
CAPTURE: a multinational, cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries
https://doi.org/10.1186/s12933-021-01344-0
Documents that mention this clinical trial
Contemporary (2019) prevalence of cardiovascular disease in adults with type 2 diabetes in Brazil: the cross-sectional CAPTURE study
https://doi.org/10.1186/s13098-021-00775-9
-
Funding
Funding for this research was provided by:
Novo Nordisk A/S
- License Information
-
More Information
Article History
Received: 30 July 2021
Accepted: 23 December 2021
First Online: 10 January 2022
Declarations
:
: The protocol was approved by the ethics committee at each participating trial site and the study was conducted in accordance with the provisions of the Declaration of Helsinki [], the International Society for Pharmacoepidemiology Good Pharmacoepidemiology Practices [], and local regulations for clinical research in Brazil. All participants provided written informed consent prior to study participation.
: Not applicable.
: SV—Research grants: Novo Nordisk, Biomm, Bayer and Cristalia; honoraria for consultancy or giving lectures: AstraZeneca, Novo Nordisk, Boehringer Ingelheim, and Novartis; he is also the Editor-in-Chief of Diabetology & Metabolic Syndrome and this article was independently handled by the Deputy Editor-in-Chief. AV—Advisory Board: Novo Nordisk, Sanofi, Biomm, Abbott Diabetes Care, and Medtronic; speaker: Novo Nordisk, Sanofi, Biomm, Abbott Diabetes Care, Servier, MSD, Medtronic, Lilly, and AstraZeneca; research Grants: Novo Nordisk, AstraZeneca, and Lilly. MS—Employee of and shareholder in Novo Nordisk. DP—Research grants: Novo Nordisk, Bayer, Boehringer Ingelheim, Novartis, Daiichi-Sankyo, Amgen, Vifor-Pharma, and AstraZeneca; advisory board: Servier and Bayer.
